{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:39:39Z","timestamp":1790368779393,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Muta university"},{"DOI":"10.13039\/501100005712","name":"University of Jordan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Familial breast cancer is estimated to account for 15\u201320% of all cases of breast cancer. Surveillance for familial breast cancer is well-established world-wide. However, this service does not exist in Jordan, due to the scarcity of information with regard to the genetic profiling of these patients, and therefore lack of recommendations for policy-makers. As such, patients with very strong family history of breast or ovarian cancers are not screened routinely; leading to preventable delay in diagnosis. Whole coding sequencing for\n                    <jats:italic>BCRA1<\/jats:italic>\n                    \/\n                    <jats:italic>BCRA2<\/jats:italic>\n                    using next-generation sequencing (NGS)\/Ion PGM System was performed. Sanger sequencing were then used to confirm the pathogenic variants detected by NGS. In this study, 192 breast cancer patients (and 8 ovarian cancer cases) were included. The prevalence of recurrent pathogenic mutations was 14.5%, while the prevalence of newly detected mutations was 3.5%. Two novel pathogenic mutations were identified in\n                    <jats:italic>BRCA2<\/jats:italic>\n                    genes. The common mutations in the Ashkenazi population used for screening may not apply in the Jordanian population, as previously reported mutations were not prevalent, and other new mutations were identified. These data will aid to establish a specific screening test for\n                    <jats:italic>BRCA 1<\/jats:italic>\n                    \/\n                    <jats:italic>BRCA2<\/jats:italic>\n                    in the Jordanian population.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-74250-2","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T06:02:55Z","timestamp":1602828175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan"],"prefix":"10.1038","volume":"10","author":[{"given":"Munir","family":"Abu-Helalah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmi","family":"Mubaidin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dema","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Jafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Alshraideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Drou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Awidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"74250_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"74250_CR2","first-page":"9","volume":"16","author":"M Al-Tarawneh","year":"2010","unstructured":"Al-Tarawneh, M., Khatib, S. & Arqub, K. Cancer incidence in Jordan, 1996\u20132005. Eastern Mediterranean Health J. 16, 9 (2010).","journal-title":"Eastern Mediterranean Health J."},{"key":"74250_CR3","first-page":"3193","volume":"58","author":"E Rhei","year":"1998","unstructured":"Rhei, E. et al. Molecular genetic characterization of BRCA1-and BRCA2-linked hereditary ovarian cancers. Cancer Res. 58, 3193\u20133196 (1998).","journal-title":"Cancer Res."},{"key":"74250_CR4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"74250_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/humu.23406","volume":"39","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck, T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 39, 593\u2013620 (2018).","journal-title":"Hum. Mutat."},{"key":"74250_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/ng1092-128","volume":"2","author":"SA Smith","year":"1992","unstructured":"Smith, S. A., Easton, D. F., Evans, D. G. R. & Ponder, B. A. J. Allele losses in the region 17q12\u201321 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 2, 128\u2013131 (1992).","journal-title":"Nat. Genet."},{"key":"74250_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1634\/theoncologist.9-1-13","volume":"9","author":"DL Thull","year":"2004","unstructured":"Thull, D. L. & Vogel, V. G. Recognition and management of hereditary breast cancer syndromes. Oncologist 9, 13\u201324 (2004).","journal-title":"Oncologist"},{"key":"74250_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"SA Narod","year":"2004","unstructured":"Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665\u2013676 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"74250_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12885-018-4079-1","volume":"18","author":"H Abdel-Razeq","year":"2018","unstructured":"Abdel-Razeq, H., Al-Omari, A., Zahran, F. & Arun, B. Germline BRCA1\/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer 18, 152 (2018).","journal-title":"BMC Cancer"},{"key":"74250_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/clinchem\/43.1.24","volume":"43","author":"EM Rohlfs","year":"1997","unstructured":"Rohlfs, E. M. et al. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin. Chem. 43, 24\u201329 (1997).","journal-title":"Clin. Chem."},{"key":"74250_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2407-7-14","volume":"7","author":"L Kadouri","year":"2007","unstructured":"Kadouri, L. et al. A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer. BMC Cancer 7, 14 (2007).","journal-title":"BMC Cancer"},{"key":"74250_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1590\/S1516-31802005000400007","volume":"123","author":"RM Dufloth","year":"2005","unstructured":"Dufloth, R. M. et al. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med. J. 123, 192\u2013197 (2005).","journal-title":"Sao Paulo Med. J."},{"key":"74250_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/humu.23842","volume":"40","author":"Y Laitman","year":"2019","unstructured":"Laitman, Y. et al. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Hum. Mutat. 40, e1\u2013e23 (2019).","journal-title":"Hum. Mutat."},{"key":"74250_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archinte.163.1.49","volume":"163","author":"CI Li","year":"2003","unstructured":"Li, C. I., Malone, K. E. & Daling, J. R. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch. Intern. Med. 163, 49\u201356 (2003).","journal-title":"Arch. Intern. Med."},{"key":"74250_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mgg3.120","volume":"3","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu, Y. et al. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol. Genet. Genom. Med. 3, 121\u2013129 (2015).","journal-title":"Mol. Genet. Genom. Med."},{"key":"74250_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/mgg3.149","volume":"3","author":"D Trujillano","year":"2015","unstructured":"Trujillano, D. et al. Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening of CFTR. Mol. Genet. Genom. Med. 3, 396\u2013403 (2015).","journal-title":"Mol. Genet. Genom. Med."},{"key":"74250_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013423 (2015).","journal-title":"Genet. Med."},{"key":"74250_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4048\/jbc.2013.16.4.357","volume":"16","author":"H Kim","year":"2013","unstructured":"Kim, H. & Choi, D. H. Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast cancer. J. Breast Cancer 16, 357\u2013365 (2013).","journal-title":"J. Breast Cancer"},{"key":"74250_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10549-017-4635-4","volume":"168","author":"A-J Alhuqail","year":"2018","unstructured":"Alhuqail, A.-J. et al. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in Arab breast and ovarian cancer patients. Breast Cancer Res. Treat. 168, 695\u2013702 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"74250_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1126\/science.7939630","volume":"266","author":"PA Futreal","year":"1994","unstructured":"Futreal, P. A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120\u2013122 (1994).","journal-title":"Science"},{"key":"74250_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/jmg.2003.015867","volume":"41","author":"V Abkevich","year":"2004","unstructured":"Abkevich, V. et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J. Med. Genet. 41, 492\u2013507 (2004).","journal-title":"J. Med. Genet."},{"key":"74250_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ng1294-399","volume":"8","author":"LS Friedman","year":"1994","unstructured":"Friedman, L. S. et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 8, 399\u2013404 (1994).","journal-title":"Nat. Genet."},{"key":"74250_CR23","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/JCO.1999.17.11.3396","volume":"17","author":"LC Verhoog","year":"1999","unstructured":"Verhoog, L. C. et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J. Clin. Oncol. 17, 3396\u20133402 (1999).","journal-title":"J. Clin. Oncol."},{"key":"74250_CR24","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1158\/1055-9965.EPI-07-0403","volume":"16","author":"P Ang","year":"2007","unstructured":"Ang, P. et al. BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy. Cancer Epidemiol. Prev. Biomark. 16, 2276\u20132284 (2007).","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"74250_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12282-013-0503-1","volume":"22","author":"S Nakamura","year":"2015","unstructured":"Nakamura, S. et al. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer 22, 462\u2013468 (2015).","journal-title":"Breast Cancer"},{"key":"74250_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ar.22628","volume":"296","author":"W Cao","year":"2013","unstructured":"Cao, W., Wang, X., Gao, Y., Yang, H. & Li, J.-C. BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer. Anatomical Rec. 296, 273\u2013278 (2013).","journal-title":"Anatomical Rec."},{"key":"74250_CR27","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ijc.30771","volume":"141","author":"S Lolas Hamameh","year":"2017","unstructured":"Lolas Hamameh, S. et al. Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53. Int. J. Cancer 141, 750\u2013756 (2017).","journal-title":"Int. J. Cancer"},{"key":"74250_CR28","first-page":"700","volume":"23","author":"E-HA El-Harith","year":"2002","unstructured":"El-Harith, E.-H.A., Abdel-Hadi, M. S., Steinmann, D. & Dork, T. BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi Med. J. 23, 700\u2013704 (2002).","journal-title":"Saudi Med. J."},{"key":"74250_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-007-9846-7","volume":"112","author":"IJ Seymour","year":"2008","unstructured":"Seymour, I. J. et al. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1\/2 germ-line mutations. Breast Cancer Res. Treat. 112, 343\u2013349 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"74250_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2407-8-140","volume":"8","author":"E Machackova","year":"2008","unstructured":"Machackova, E. et al. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and\/or ovarian cancer. BMC Cancer 8, 140 (2008).","journal-title":"BMC Cancer"},{"key":"74250_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1186\/s12885-016-2966-x","volume":"16","author":"S Maistro","year":"2016","unstructured":"Maistro, S. et al. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. BMC Cancer 16, 934 (2016).","journal-title":"BMC Cancer"},{"key":"74250_CR32","doi-asserted-by":"publisher","first-page":"e62468","DOI":"10.1371\/journal.pone.0062468","volume":"8","author":"E Tram","year":"2013","unstructured":"Tram, E., Savas, S. & Ozcelik, H. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2. PLoS ONE 8, e62468 (2013).","journal-title":"PLoS ONE"},{"key":"74250_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117\u20131130 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"74250_CR34","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ejca.2005.11.032","volume":"42","author":"F Lalloo","year":"2006","unstructured":"Lalloo, F. et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur. J. Cancer 42, 1143\u20131150 (2006).","journal-title":"Eur. J. Cancer"},{"key":"74250_CR35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3322\/caac.20128","volume":"61","author":"JN Weitzel","year":"2011","unstructured":"Weitzel, J. N., Blazer, K. R., MacDonald, D. J., Culver, J. O. & Offit, K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J. Clin. 61, 327\u2013359 (2011).","journal-title":"CA Cancer J. Clin."},{"key":"74250_CR36","doi-asserted-by":"crossref","unstructured":"Cm, J.-R. et al. Women\u2019s Attitudes Toward Preventive Strategies for Hereditary Breast or Ovarian Carcinoma Differ From One Country to Another: Differences Among English, French, and Canadian Women. Cancer vol. 92 https:\/\/pubmed.ncbi.nlm.nih.gov\/11550171\/ (2001).","DOI":"10.1002\/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V"},{"key":"74250_CR37","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2147\/CMAR.S189627","volume":"11","author":"C Forbes","year":"2019","unstructured":"Forbes, C., Fayter, D., de Kock, S. & Quek, R. G. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag. Res. 11, 2321 (2019).","journal-title":"Cancer Manag. Res."},{"key":"74250_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/tbj.12541","volume":"22","author":"M Ahmad Abu-Helalah","year":"2016","unstructured":"Ahmad Abu-Helalah, M. et al. Delay in presentation, diagnosis, and treatment for breast cancer patients in Jordan. Breast J. 22, 213\u2013217 (2016).","journal-title":"Breast J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74250-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74250-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74250-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T20:23:57Z","timestamp":1723753437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74250-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74250"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74250-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"29 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17573"}}